PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
11.15%
Revenue growth 1.25-1.5x MCHP's 9.46%. Bruce Berkowitz would check if differentiation or pricing power justifies outperformance.
8.67%
Gross profit growth at 75-90% of MCHP's 10.95%. Bill Ackman would demand operational improvements to match competitor gains.
-18.95%
Negative EBIT growth while MCHP is at 15.31%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-14.93%
Negative operating income growth while MCHP is at 15.20%. Joel Greenblatt would press for urgent turnaround measures.
-47.61%
Negative net income growth while MCHP stands at 14.51%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-48.68%
Negative EPS growth while MCHP is at 16.64%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-47.22%
Negative diluted EPS growth while MCHP is at 12.15%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
0.47%
Slight or no buybacks while MCHP is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
-4.07%
Reduced diluted shares while MCHP is at 0.62%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
2.45%
Dividend growth of 2.45% while MCHP is flat. Bruce Berkowitz would see if this can become a bigger advantage long term.
-23.75%
Negative OCF growth while MCHP is at 0.37%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-222.99%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
42.96%
10Y revenue/share CAGR under 50% of MCHP's 247.49%. Michael Burry would suspect a lasting competitive disadvantage.
-19.24%
Negative 5Y CAGR while MCHP stands at 144.18%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
13.52%
3Y revenue/share CAGR under 50% of MCHP's 58.73%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
2418.16%
10Y OCF/share CAGR above 1.5x MCHP's 488.41%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
-16.24%
Negative 5Y OCF/share CAGR while MCHP is at 444.64%. Joel Greenblatt would question the firm’s operational model or cost structure.
-19.88%
Negative 3Y OCF/share CAGR while MCHP stands at 351.31%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
7472.52%
Net income/share CAGR above 1.5x MCHP's 361.00% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
105.66%
5Y net income/share CAGR at 50-75% of MCHP's 188.12%. Martin Whitman might see a shortfall in operational efficiency or brand power.
-64.38%
Negative 3Y CAGR while MCHP is 91.70%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
287.85%
10Y equity/share CAGR at 50-75% of MCHP's 485.79%. Martin Whitman would note a lag in capital accumulation vs. the competitor.
182.94%
5Y equity/share CAGR at 75-90% of MCHP's 227.07%. Bill Ackman might push for an improved ROE or share repurchase strategy to keep up.
76.79%
3Y equity/share CAGR at 75-90% of MCHP's 101.55%. Bill Ackman pushes for margin or operational changes to match the competitor’s pace.
15.66%
Dividend/share CAGR of 15.66% while MCHP is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
-4.26%
Negative 5Y dividend/share CAGR while MCHP stands at 0.00%. Joel Greenblatt sees a weaker commitment to dividends vs. a competitor that might be growing them.
-1.77%
Negative near-term dividend growth while MCHP invests at 0.00%. Joel Greenblatt sees a weaker short-term distribution policy unless justified by strategic spending.
12.58%
AR growth well above MCHP's 0.96%. Michael Burry fears inflated revenue or higher default risk in the near future.
10.11%
We show growth while MCHP is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
-6.23%
Negative asset growth while MCHP invests at 12.15%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-2.27%
We have a declining book value while MCHP shows 10.57%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
4.89%
Debt shrinking faster vs. MCHP's 13788.89%. David Dodd sees a safer balance sheet if it doesn't impair future growth.
33.25%
R&D growth drastically higher vs. MCHP's 13.88%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
13.25%
SG&A growth well above MCHP's 2.40%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.